Quotient Bioresearch and KWS BioTest partner to deliver end-to-end anti-infectives screening

Cambridge, UK & Bristol, UK, 9 May 2011 – Leading drug development service
providers, Quotient Bioresearch Ltd. and KWS BioTest Ltd., have today announced a new
strategic partnership to provide a novel co-ordinated approach to support the discovery
and development of new antimicrobial agents.

The partnership – unveiled at the 21st European Congress of Clinical Microbiology and
Infectious Diseases 2011 (ECCMID 2011) in Milan, Italy – will enable the two companies
to provide high quality screening of anti-infectives all the way from in vitro activity
assays, efficacy and resistance profiling through validated models of human disease to
surveillance and clinical investigations, with full scientific support.

Dr. Ian Morrissey, Director of Anti-Infectives at Quotient, explained: “With KWS we can
provide a unique and fully-integrated ‘Plate to Patient’ offering for our anti-infective
clients, by now including anti-virals and models of human disease.”

The new partnership has been created following a longstanding relationship between
Quotient and KWS and represents significant expansion in the industry for both
companies. Sharing a number of joint customers, the synergy created through this
collaboration will enable both companies to carry out larger integrated studies with
associated added value and efficiencies for their clients.

Prof. Neil Williams, Director of Science at KWS BioTest, is excited to formalise an
agreement with Quotient. He commented: “Both companies have established themselves
on a basis of providing a high quality of service, scientific understanding and support to
their clients.”

Download press release